Skip to main content
. 2017 Feb 28;8(14):23702–23712. doi: 10.18632/oncotarget.15784

Figure 6. Treatment response of BRCA2-deficient (PEO1) and BRCA2-wild-type (PEO4) ovarian carcinoma cells to evofosfamide and irradiation.

Figure 6

(A) Cells were pre-incubated in hypoxia (0.2% O2) for 20 hours, followed by treatment with increasing concentrations of evofosfamide for 4 hours. The proliferative activity of reoxygenated cells was monitored over 72 hours. (B) Clonogenic cell survival assay of BRCA2 deficient (PEO1) and wild-type (PEO4) cells in response to evofosfamide (0.5 μM) and irradiation with 4 Gy. Cells were pre-incubated in hypoxia (0.2% O2) for 20 hours, followed by evofosfamide treatment under hypoxic conditions (4 hours), reoxygenation and irradiation with 4 Gy. Error bars represent SEM.